Quoin Pharmaceuticals
QNRX
5 hedge funds and large institutions have $674K invested in Quoin Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
400% more funds holding
Funds holding: 1 → 5 (+4)
97% more capital invested
Capital invested by funds: $342K → $674K (+$332K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$69.8K |
| 2 |
HF
HRT Financial
New York
|
+$69.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$69.8K |
| 4 |
VF
Virtu Financial
New York
|
+$69.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$69.8K |
QNRX Hedge Fund Activity: Q1 2021 in Review
5 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2021, worth a combined $674K — up 97% from $342K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new QNRX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $69.8K. The largest seller was Renaissance Technologies, cutting an estimated $69.8K.
- 5 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2021, up from 1 in Q4 2020.
- Funds reported $674K of Quoin Pharmaceuticals stock for Q1 2021, up 97% quarter-over-quarter.
- 4 funds opened new Quoin Pharmaceuticals positions in Q1 2021 and 0 closed out, a net change of +4 holders.
- The largest Quoin Pharmaceuticals buyer in Q1 2021 was Citadel Advisors, an estimated $69.8K added.
- The largest Quoin Pharmaceuticals seller in Q1 2021 was Renaissance Technologies, an estimated $69.8K sold.
Based on aggregated 13F filings for Q1 2021.